In the forefront of life science, how non-coding RNAs (IncRNAs, circRNAs, miRNAs) and RNA-binding proteins (RBPs) regulate tumorigenesis, metastasis, and stem cell characteristics is a core research focus. Revealing the direct interactions between RNA and protein, and between RNA and RNA, is the key to elucidating their molecular mechanisms and also the most challenging part of the experiment.
GeneCreate has long been focused on the technological research and development and product optimization in the field of molecular interactions. Its RIP (RNA Immunoprecipitation) and RNA pull-down Kits have been recognized by many scientific researchers due to their stable performance and good repeatability. Recently, several research papers published in journals such as Nature Communications, Journal of Translational Medicine, Cancer Gene Therapy, etc. have all used GeneCreate's RIP or RNA pull-down Kits, providing key experimental evidence for clarifying the RNA regulatory network in complex diseases.
The following is a summary of 5 representative literatures recently published using GeneCreate's RIP and RNA pull-down Kits, fully demonstrating the application value of Genecreate's products in scientific research:
Cooperative Literature 1
Published Journal: Nature Communications (IF: 15.7)
Cooperating Institution: Xinqiao Hospital of Army Medical University
GeneCreate Product: RIP Kit
Research Overview:
Intervertebral disc degeneration (IDD) is a major cause of low back pain, and its pathological features are a vicious cycle of oxidative stress, ferroptosis, and inflammation. In this study, a nanozyme-loaded dynamic hydrogel PG@MBC was developed,which can effectively scavenge reactive oxygen species (ROS),inhibit ferroptosis, and reduce the stability of IL6 mRNA by inhibiting the expression of HuR protein and its binding to IL6 mRNA, thereby blocking the inflammatory response mediated by the IL6/STAT3 signaling axis.
Key applications of Kingcare products:
To clarify the molecular mechanism of PG@MBC in inhibiting inflammation, the research team used GeneCreate's RIP kit to verify the direct binding of the RNA-binding protein HuR to IL6 mRNA. The results showed that in degenerated nucleus pulposus cells, HuR protein could significantly enrich IL6 mRNA; after treatment with PG@MBC, the binding of HuR to IL6 mRNA was significantly weakened, and the stability of HuR protein was reduced. This finding reveals the deep mechanism of PG@MBC in exerting anti-inflammatory effects by regulating the HuR/IL6 axis.
Cooperative literature 2
Cooperating institution: The Affiliated Hospital of Qingdao University
GeneCreate product: RNA pull-down kit
Research overview:
The RNA-binding protein FUS is highly expressed in renal cell carcinoma (RCC) and is associated with poor prognosis of patients. Mechanistic studies have shown that FUS interacts with the KCMF1 protein, and overexpression ofKCMF1 can promote the translocation of FUS into the nucleus. After entering the nucleus, FUS directly binds to CENPT mRNA and upregulates its expression, thereby activating the JNK signaling pathway and promoting the proliferation, migration, and invasion of renal cancer cells.
Key applications of Kingcare products:
To verify the direct binding ofFUS to CENPT mRNA, the research team used the RNA pull-down kit from GeneCreate. The specific method was as follows: in vitro transcribed biotin-labeled CENPT RNA was used as a "bait" to capture the interacting proteins in cell lysates.
The Western blot results showed that FUS protein was specifically enriched by the CENPT RNA probe, while this phenomenon was not observed in the control group. This experiment provided direct evidence for "FUS regulates the expression ofCENPT mRNA by directly binding to it".
Cooperative literature 3
Publication: Journal of Translational Medicine (IF:7.5)
Cooperating institution: The Affiliated Tumor Hospital of Harbin Medical University
GeneCreate product: RIP kit
Research overview:
The transcription factor ETV1 is highly expressed in multiple myeloma (MM) and is associated with poor prognosis in patients. Mechanistic studies have shown that METTL3-mediated m6A methylation modification enhances the stability of ETV1 mRNA, leading to its upregulation. ETV1 then acts as a transcription factor, directly binds to the promoter region of RBMS1 and activates its transcription, thereby promoting the proliferation of MM cells and the M2 polarization of tumor-associated macrophages (TAM).
Key applications of KingCheer products:
To verify the direct binding of METTL3 to ETV1 mRNA, the research team used the RIP kit from GeneCreate.
The specific method was as follows: RIP was performed using an anti-METTL3 antibody, followed by qPCR detection.
The results showed that compared with the control group IgG, the METTL3 antibody could significantly enrich ETV1 mRNA, confirming the direct binding of METTL3 to ETV1 mRNA and providing key experimental evidence for "METTL3 regulates the expression of ETV1 through m6A modification".
Cooperative literature 4
Published journal: Cancer Gene Therapy (IF: 5.0)
Cooperating institution: Fudan University Shanghai Cancer Center
GeneCreate products: RNA pull-down kit, RIP kit
Research overview:
Long non-coding RNA NRAV is highly expressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis of patients. This study found that NRAV is modified by m6A methylation, sponges hsa-let-7c-5p through the ceRNA mechanism, relieves its inhibition on the downstream stem cell factor LIN28B, thereby enhancing the stem cell characteristics of hepatocellular carcinoma cells and promoting tumor growth.
Key applications of GeneCreate products:
To verify the direct binding of NRAV and let-7c-5p, the research team used GeneCreate's RNA pull-down kit. Pull-down was performed with a biotin-labeled NRAV probe, and qRT-PCR detection showed that NRAV could specifically enrich let-7c-5p, while the control probe had no such effect.
This experiment directly confirmed the physical interaction between NRAV and let-7c-5p, providing core evidence for elucidating the molecular mechanism of NRAV as a ceRNA.
Cooperative literature 5
Published journal: Cancer Science (IF: 4.3)
Research institution: The Affiliated Hospital of Nantong University
GeneCreate products: RNA pull-down kit, RIP kit
Research overview:
Circular RNA circ-0030167 was significantly down regulated in pancreatic cancer tissues and was associated with a good prognosis in patients. Mechanistic studies showed that circ-0030167 could directly bind to the RNA-binding protein IGF2BP1 and enhance its protein stability.
Subsequently, IGF2BP1 stabilized HMOX1 mRNA by recognizing the m6A modification site on HMOX1 mRNA, thereby inducing mitophagy-mediated ferroptosis and inhibiting the progression of pancreatic cancer.
Key applications of GeneCreate products:
In this study, GeneCreate's RNA pull-down and RIP kits were used in combination to form a complete evidence chain of RNA-protein interaction:
RNA pull-down experiment: A biotinylated circ-0030167 probe was used to capture interacting proteins from cell lysates.
Combining mass spectrometry analysis and Western blot verification, IGF2BP1 was successfully identified as a key binding protein of circ-0030167.
RIP experiment: RIP was performed using an anti-IGF2BP1 antibody, and combined with qPCR detection,it was reversely confirmed the endogenous binding of IGF2BP1 to circ-0030167.
These two experiments complement each other, verifying the specific interaction between circ-0030167 and IGF2BP1 from both positive and negative directions, laying a solid foundation for subsequent functional studies.
The above 5 high-quality studies cover disease areas such as liver cancer, pancreatic cancer,kidney cancer, multiple myeloma, and intervertebral disc degeneration.
They jointly verified a fact: GeneCreate's RIP and RNA pull-down kits, with their stable quality and good experimental performance, have become reliable tools in the study of RNA-protein and RNA-RNA interaction mechanisms.
Whether exploring the regulatory network of IncRNA/circRNA or analyzing the downstream targets of RNA-binding proteins, GeneCreate can provide you with a complete solution from reagents to technical services.
References
[1]Wang Y, Tan L, Yang Y, Duan H, Liu C, Zhao J, Zhou Y, Li C, Liu M. Targeting the ROS-ferroptosis-inflammation cycle with a nanozyme-functionalized hydrogel for intervertebral disc repair. Nat Commun. 2025 Nov 20;16(1):11253.
[2]Jiang Z, Zhang R, Qi Y, Li Y, Zhu G, Zhao K, Yin X, Li X, Yang H, Yan X, Li Z, He T, Wang K, Zhang Z. Fused in Sarcoma (FUS) promotes renal cell carcinoma progression via the KCMF1/FUS/CENPT axis and activation of the JNK signaling pathway. J Transl Med. 2025 Nov 3;23(1):1207.
[3]Liu Y, Geng Y, Zheng B, Zhang A, Yang K, Mao Y, Jiang L. m6A methylation-modified ETV1 drives multiple myeloma progression and M2 polarization of tumor-associated macrophage through transcriptional activation of RBMS1. J Transl Med. 2026 Feb 13;24(1):394.
[4]Chen Y, Dai S, Zhuang L, Cai W, Chen H, Zhao J, Zhang F, Chen L, Cheng CS. NRAV promotes HCC stemness via the m6A-regulated let-7c-5p/LIN28B axis. Cancer Gene Ther. 2026 Feb;33(2):171-185.
[5]Zhao Q, Yao X, Lu J, Chen Q, Wang Z, Li X, Lu Y. Circ-0030167/IGF2BP1 Induces Mitophagy-Mediated Ferroptosis via HMOX1 mRNA Stabilization in Pancreatic Cancer. Cancer Sci. 2026 May;117(5):1362-1379.